Welcome to our dedicated page for PERRIGO news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on PERRIGO stock.
Perrigo Company plc reports recurring developments as a pure-play consumer health company focused on over-the-counter self-care products, store-brand private label offerings, and branded health and wellness products primarily in North America and Europe. Company updates cover operating results from continuing operations, category performance, dividends, investor presentations, and portfolio actions under its Three-S plan to stabilize, streamline, and strengthen the business.
News also addresses Perrigo's product-category reporting and brand momentum across Self Care and Specialty Care, including names such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®. Recent corporate developments include the completed divestiture of the Dermacosmetics business and the use of portfolio proceeds for balance-sheet debt reduction.
Perrigo Company plc (NYSE: PRGO) is set to release its second quarter 2022 financial results on August 9, 2022, with a conference call scheduled for 8:30 A.M. EDT. The call will be accessible via webcast on the investor relations section of the Perrigo website. A replay will be available shortly after the call until August 16, 2022.
Perrigo is a leading provider of Consumer Self-Care Products and OTC health solutions, focusing on enhancing individual well-being.
Perrigo Company plc (NYSE: PRGO) announced that HRA Pharma has submitted an application to the FDA for the first-ever over-the-counter birth control pill, Opill®. This progestin-only pill aims to increase contraceptive access in the U.S., potentially reducing the high rate of unintended pregnancies, which number over 6.1 million annually. Major medical organizations support this initiative, underscoring its significance in reproductive health. If approved, Opill® would be the first OTC daily birth control pill available without a prescription in the U.S.
Perrigo Company plc (NYSE: PRGO) has appointed Ms. Alison Ives as Executive Vice President and Chief Scientific Officer. Ms. Ives will oversee global research and development and regulatory efforts, joining the Company’s Operating Committee. CEO Murray S. Kessler emphasized her 20 years of experience, highlighting her role in enhancing Perrigo's product portfolio, which now has over $500 million in potential revenue. Ms. Ives expressed confidence in delivering innovation with her team at Perrigo, reinforcing the company's commitment to consumer self-care.
Perrigo Company plc (NYSE: PRGO) announced that President and CEO Murray S. Kessler and CFO Eduardo Bezerra will engage in investor meetings at the Credit Suisse HALO Investment Summit in New York City on May 25, 2022, with no formal presentation planned.
Kessler is also set to virtually present at the Oppenheimer Consumer Growth and E-Commerce Conference on June 15, 2022, at 9:45 AM EDT. Interested parties can access webcasts via the Perrigo website. Perrigo is a leading provider of consumer self-care products, ranking as the largest store brand OTC player in the U.S.
Perrigo reported first quarter 2022 net sales of $1.1 billion, reflecting a 6.4% increase from the previous year, with organic growth at 9.7%. The loss per diluted share was $0.01, compared to an earnings per share of $0.02 last year. Adjusted diluted EPS dropped to $0.33 from $0.50, impacted by cost headwinds and foreign exchange fluctuations. The acquisition of HRA Pharma bolstered sales expectations, prompting an increase in fiscal 2022 net sales growth guidance to 8.5%-9.5% from 3.5%-4.5%.
Perrigo Company plc (NYSE: PRGO) has announced the succession of its executive leadership team. Eduardo Bezerra will become Chief Financial Officer on May 16, 2022, succeeding Ray Silcock, who will retire on July 15, 2022. Todd Kingma, the current EVP and General Counsel, will retire on August 31, 2022, with Kyle Hanson named as his successor, effective June 1, 2022. CEO Murray Kessler emphasized that these appointments are essential to advancing Perrigo's consumer self-care strategy and operational excellence.
Perrigo Company plc (NYSE: PRGO) declared a quarterly dividend of $0.26 per share, set for payment on June 21, 2022, to shareholders on record as of June 3, 2022. As a prominent global provider of Consumer Self-Care Products, Perrigo continues to lead in the OTC market in the U.S. and ranks among the top players in Europe. This dividend is a demonstration of the company's commitment to returning value to its shareholders and indicates confidence in its ongoing business strategy.
Perrigo Company plc (NYSE: PRGO) announced the completion of its acquisition of Héra SAS for €1.8 billion (approximately $1.9 billion) in cash on April 29, 2022. This strategic move is intended to enhance Perrigo's position in the consumer self-care market. CEO Murray Kessler highlighted that the acquisition aligns with the company's transformation plan, aiming for improved sales, earnings growth, and margin enhancement. The integration of HRA is set to expand Perrigo's geographic reach and drive innovation in self-care products.
Perrigo Company plc (NYSE: PRGO) announced that the acquisition of Héra SAS is expected to close on April 29, 2022, pending the satisfaction of remaining conditions in the sale agreement. This acquisition aligns with Perrigo's strategy as a leading provider of self-care products in the OTC market, enhancing its presence in the health and wellness sector. The company asserts its commitment to empowering consumers with affordable self-care solutions, reinforcing its market position.
Perrigo Company plc (NYSE: PRGO) will announce its first quarter 2022 financial results on May 11, 2022, at 8:30 A.M. (EDT). The conference call will be accessible via webcast on the investor relations section of Perrigo's website. A replay will also be available from 12:00 P.M. (EDT) on May 11 until midnight on May 18, 2022. Perrigo is a significant player in the Consumer Self-Care Products sector, being the largest store brand OTC provider in the U.S. and a top OTC company in Europe.